Organ targeting with the oral progestin dienogest

Drugs of Today

Volumn 32, Issue SUPPL. H, 1996, Pages 43-55

  Graser T ^a   Oettel, M ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORMADINONE ACETATE; DESOGESTREL; DIENOGEST; GESTAGEN; GESTODENE; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; NORETHISTERONE ACETATE; NORGESTIMATE;

CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CONFERENCE PAPER; DRUG STRUCTURE; FEMALE; HORMONAL CONTRACEPTION; HORMONE SUBSTITUTION; HUMAN; ORAL DRUG ADMINISTRATION; RISK FACTOR;

EID: 0030464378     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Hsueh, A.J.W. Designer contraceptive pills. Human Reprod 1995, 10: 1997-2000.
2. Gal, D., Weiselberg, L, Runowicz, C.D. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994, 86: 1252-3.
3. McDonnell, D.P., Clevenger, B., Dana, S., Santiso-Mere, D., Tzukerman, M.T., Gleeson, M.A. The mechanism of action of steroid hormones: A new twist to an old tale. J Clin Pharmacol 1993, 33: 1165-72.
4. Oettel, M., Bervoas-Martín, B., Elger, W. et al. A 19-norprogestin without a 17α-ethinyl group. I: Dienogest from a pharmacokinetic point of view. Med Actual/Drugs Today 1995, 31: 499-516.
5. Oettel, M., Carol, W., Elger, W. et al. A 19-norprogestin without a 17α-ethinyl group. II: Dienogest from a pharmacodynamic point of view. Med Actual/Drugs Today 1995, 31: 517-36.
6. Moore, C., Walter, F., Klinger, G., Carol, W, Influence of dienogest on the ovulation and various endocrinological parameters in young women. In: Dienogest. Preclinical and Clinical Features of a Unique Progestogen, 2nd Edition. Teichmann, A.T. (Ed.). Walter de Gruyter: Berlin 1995, 161-9.
7. Fitzgerald, C., Feichtinger, W., Spona, J. et al. A comparison of the effects of two monophasic low dose oral contraceptives on the inhibition of ovulation. Adv Contracept 1994, 10: 5-18.
8. Schleussner, E., Michels, W., Bethge, S., Klinger, G. Effect of dienogest on the hypothalamo-pituitary axis: A pilot study. In: Dienogest. Preclinical and Clinical Features of a Unique Progestogen, 2nd Edition. Teichmann, A.T. (Ed.). Walter de Gruyter: Berlin 1995, 171-9.
9. Köhler, G. Treatment of endometriosis with dienogest: A renaissance of progestogens. In: Dienogest. Preclinical and Clinical Features of a Unique Progestogen, 2nd Edition. Teichmann, A.T. (Ed.). Walter de Gruyter: Berlin 1995, 243-51.
10. Hulka, B.S. Links between hormone replacement therapy and neoplasia. Fertil Steril 1994, 62: S168-75.
11. Udoff, L., Langenberg, P., Adashi, E.Y. Combined continuous hormone replace-ment therapy: A critical review. Obstet Gynecol 1995, 86: 306-16.
12. Archer, D.F., Pickar, J.H., Bottiglioni, F. for the Menopause Study Group. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Obstet Gynecol 1994, 83: 686-92.
13. Rauch, U., Taubert, H.D. Continuous hormone replacement therapy with estradiol valerate and chlormadinone acetate in adjustable doses. A preliminary study. Maturitas 1993, 17: 123-7.
14. Staland, B. Continuous treatment with natural oestrogens and progestogens: A method to avoid endometrial stimulation. Maturitas 1981, 3: 145-56.
15. Barrett-Connor, E. Postmenopausal estrogen and heart disease. Atherosclerosis 1995, 118: S7-10.
16. Gordon, D.J. HDL and CHD - An epidemiological perspective. J Drug Dev 1990, 3: 11.
17. Gilligan, D.M., Badar, D.M., Panza, J.A., Quyyumi, A.A., Cannon, R.O. Acute vascular effects of estrogens in postmenopausal women. Circulation 1994, 90: 786-91.
18. Nègre-Salvayre, A., Pieraggi, M.T., Mabile, L., Salvayre, R. Protective effect of 17β-estradiol against the cytotoxicity of minimally oxidized LDL to cultured bovine aortic endothelial cells. Atherosclerosis 1993, 99: 207-17.
19. Mück, A.O., Seeger, H., Korte, K., Lippert, T.H. Effect of estradiol on calcium influx in human umbilical cord endothelial cells. Med Sci Res 1994, 22:19.
20. Mück, A.O., Seeger, H., Lippert, T.H. Effect of estradiol and dienogest on the calcium influx in cell cultures of human vessels. In: Dienogest. Preclinical and Clinical Features of a Unique Progestogen, 2nd Edition. Teichmann, A.T. (Ed.). Walter de Gruyter: Berlin 1995, 135-9.
21. Mishell, D.R.J. Contraception. New Engl J Med 1989, 320: 777-87.
22. Colditz, G.A., Hankinson, S.E., Hunter, D.J. et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. New Engl J Med 1995, 332: 1589-93.
23. Parazzini, F., Colli, E., Scatigna, M., Tozzi, L. Treatment with tamoxifen and progestins for metastatic breast cancer in postmenopausal women - A quantitative review of published randomized clinical trials. Oncology 1993, 50: 483-9.
24. Schoonen, W.G.E.J., Joosten, J.W.H., Kloosterboer, H.J. Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells. 1. MCF-7 cell lines. J Steroid Biochem Mol Biol 1995, 55: 423-37.
25. Blagosklonny, M.V., Neckers, L.M. Cytostatic and cytotoxic activity of sex steroids against human leukemia cell lines. Cancer Lett 1994, 76: 81-6.
26. Kuhl, H. Risk of developing breast cancer by taking oral contraceptives. Der Frauenarzt 1994, 35: 99-105.